Researchers

IWASA Tsutomu

IWASA Tsutomu
Associate Professor
Faculty Kindai University Nara Hospital
Researchmap https://researchmap.jp/iwasa_t

Education and Career

Education

  • 1997/04 - 2003/03 , Kindai University, Faculty of Medicine,
  • 2005/04 - 2008/03 , Kindai University, Faculty of Medicine, Graduate school of Medical science, Department of Medical Oncology,

Academic & Professional Experience

  • Apr. 2014 - Today , Kindai University, Faculty of Medicine Department of Medical Oncology Lucture
  • Sep. 2012 - Mar. 2014 , Kindai University, Faculty of Medicine Department of Medical Oncology Assistant professor
  • Jul. 2010 - Aug. 2012 , Dana-Farber Cancer Institute Posdoc fellow
  • May. 2010 - Jun. 2010 , Kindai University, Faculty of Medicine Department of Medical Oncology Assistant professor
  • Apr. 2009 - Apr. 2010 , National Hospital Organization Minami Wakayama Medical Center Department of respiratory medicine Staff
  • Apr. 2003 - Mar. 2008 , Kindai University, Faculty of Medicine Department of Medical Oncology Assistant Professor

Research Activities

Research Areas

  • Life sciences , Genomics
  • Life sciences , Tumor diagnostics and therapeutics
  • Life sciences , Tumor biology
  • Life sciences , Internal medicine - General

Published Papers

  1. Efficacy and safety of eribulin mesylate vs. docetaxel or paclitaxel, combined with trastuzumab and pertuzumab, as first-line treatment for HER2-positive locally advanced or metastatic breast cancer: updated subgroup analyses of JBCRG-M06/EMERALD.
    Norikazu Masuda; Shigehira Saji; Yasuyuki Kojima; Masahiro Kitada; Hiroshi Tada; Tsutomu Iwasa; Kei Koizumi; Tsuguo Iwatani; Yasuaki Sagara; Takashi Kuwayama; Masafumi Shimoda; Tatsunari Sasada; Koichiro Tsugawa; Yoshihiro Kawaguchi; Akihiko Shimomura; Takuhiro Yamaguchi; Hiroki Hasegawa; Shun Osaka; Satoshi Morita; Toshinari Yamashita
    Breast cancer research and treatment  218  (1)  8, Jul. 2026 
  2. Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer.
    Tsuguo Iwatani; Norikazu Masuda; Shigehira Saji; Takuhiro Yamaguchi; Yasuyuki Kojima; Masahiro Kitada; Hiroshi Tada; Tsutomu Iwasa; Kei Koizumi; Hideo Shigematsu; Yasuaki Sagara; Toshitaka Okuno; Yoshie Hasegawa; Eriko Tokunaga; Tadahiko Shien; Uhi Toh; Hiroki Hasegawa; Shun Osaka; Satoshi Morita; Toshinari Yamashita
    Breast cancer (Tokyo, Japan)  10, Jun. 2026 
  3. Spatial single-cell proteotyping reveals immunotherapy-resistant features within the complex tumor microenvironment of metastatic NSCLC
    Kohsuke Isomoto; Koji Haratani (co-first author and corresponding author); Takahiro Tsujikawa; Shuta Tomida; Yusuke Makutani; Masayuki Takeda; Kimio Yonesaka; Kaoru Tanaka; Tsutomu Iwasa; Kazuko Sakai; Kazuto Nishio; Akihiko Ito; Kazuhiko Nakagawa; Hidetoshi Hayashi
    Journal of Clinical Investigation  10, Mar. 2026  , Refereed

MORE

Conference Activities & Talks

  1. Retrospective study of chemotherapy for elderly patients for breast cancer , Tsutomu Iwasa , 2018 Japanese Society of Medical Oncology Annual Meeting , 20, Jul. 2018
  2. Phase II trial of Eribulin and S-1 combination therapy for advanced or recurrent breast cancer , Tsutomu Iwasa , ESMO ASIA 2017 , 18, Nov. 2017
  3. Retrospective analysis of 74 breast cancer patients with Eribulin treatment , Tsutomu Iwasa , 2017 Japanese Society of Medical Oncology Annual Meetinng , 27, Jul. 2017

MORE

MISC

  1. Decision-Making Support for Treatment Choice in Three Cancer Patients with Cognitive Impairment , 中尾有花; 岩朝勤; 竹久志穂; 菰池佳史; 林秀敏 , 日本臨床腫瘍学会学術集会(CD-ROM) , 22nd , 2025
  2. BRCA1/2 Reversion Mutations in Japanese Patients with MBC Progressing on Olaparib: OLIVE, WJOG15321B , 酒井瞳; 松尾理加; 細永真理; 能澤一樹; 二村学; 田辺裕子; 向原徹; 北川智余恵; 遠山竜也; 八十島宏行; 渡邉法之; 境秀樹; 岩朝勤; 竹内信道; 多田寛; 坂井和子; 千葉奈津子; 中村清吾; 高野利実; 鶴谷純司 , 日本乳癌学会学術総会(CD-ROM) , 33rd , 2025
  3. 長期生存を得た切除不能食道癌患者における治療後に生じた他臓器癌の検討 , 渡部亮太郎; 三谷誠一郎; 大倉將生; 稲垣千晶; 谷崎潤子; 田中薫; 岩朝勤; 米阪仁雄; 林秀敏 , 日本内科学会雑誌 , 114 , 2025

MORE